On June 10, 2025, FibroGen, Inc. announced a 1-for-25 reverse stock split to comply with Nasdaq rules, effective June 16, 2025, approved by stockholders earlier that month. This move is intended to raise the stock’s minimum bid price by reducing the number of shares outstanding.